Since targeting of PB/PC is one major rationale for CD38-directed treatment in SLE, we analyzed whether subsets of PB/PC expressed similar levels of CD38, and hence stratified IgA+ and IgA− PB/PC, and HLA-DRhigh PB vs. HLA-DRlow PC. The gene discussed is CD79A; the disease is systemic lupus erythematosus.